Cargando…

Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis

Study question What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults? Methods This was a systematic review including qualitative assessment and meta-analyses...

Descripción completa

Detalles Bibliográficos
Autores principales: Amick, Halle R, Gartlehner, Gerald, Gaynes, Bradley N, Forneris, Catherine, Asher, Gary N, Morgan, Laura C, Coker-Schwimmer, Emmanuel, Boland, Erin, Lux, Linda J, Gaylord, Susan, Bann, Carla, Pierl, Christiane Barbara, Lohr, Kathleen N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673103/
https://www.ncbi.nlm.nih.gov/pubmed/26645251
http://dx.doi.org/10.1136/bmj.h6019
_version_ 1782404667341275136
author Amick, Halle R
Gartlehner, Gerald
Gaynes, Bradley N
Forneris, Catherine
Asher, Gary N
Morgan, Laura C
Coker-Schwimmer, Emmanuel
Boland, Erin
Lux, Linda J
Gaylord, Susan
Bann, Carla
Pierl, Christiane Barbara
Lohr, Kathleen N
author_facet Amick, Halle R
Gartlehner, Gerald
Gaynes, Bradley N
Forneris, Catherine
Asher, Gary N
Morgan, Laura C
Coker-Schwimmer, Emmanuel
Boland, Erin
Lux, Linda J
Gaylord, Susan
Bann, Carla
Pierl, Christiane Barbara
Lohr, Kathleen N
author_sort Amick, Halle R
collection PubMed
description Study question What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults? Methods This was a systematic review including qualitative assessment and meta-analyses using random and fixed effects models. Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature were searched from January1990 through January 2015. The 11 randomized controlled trials included compared a second generation antidepressant CBT. Ten trials compared antidepressant monotherapy with CBT alone; three compared antidepressant monotherapy with antidepressant plus CBT. Summary answer and limitations Meta-analyses found no statistically significant difference in effectiveness between second generation antidepressants and CBT for response (risk ratio 0.91, 0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change in 17 item Hamilton Rating Scale for Depression score (weighted mean difference, −0.38, −2.87 to 2.10). Similarly, no significant differences were found in rates of overall study discontinuation (risk ratio 0.90, 0.49 to 1.65) or discontinuation attributable to lack of efficacy (0.40, 0.05 to 2.91). Although more patients treated with a second generation antidepressant than receiving CBT withdrew from studies because of adverse events, the difference was not statistically significant (risk ratio 3.29, 0.42 to 25.72). No conclusions could be drawn about other outcomes because of lack of evidence. Results should be interpreted cautiously given the low strength of evidence for most outcomes. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with CBT, and many of the included trials had methodological shortcomings that may limit confidence in some of the findings. What this study adds Second generation antidepressants and CBT have evidence bases of benefits and harms in major depressive disorder. Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences. Funding, competing interests, data sharing This project was funded under contract from the Agency for Healthcare Research and Quality by the RTI-UNC Evidence-based Practice Center. Detailed methods and additional information are available in the full report, available at http://effectivehealthcare.ahrq.gov/.
format Online
Article
Text
id pubmed-4673103
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-46731032015-12-18 Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis Amick, Halle R Gartlehner, Gerald Gaynes, Bradley N Forneris, Catherine Asher, Gary N Morgan, Laura C Coker-Schwimmer, Emmanuel Boland, Erin Lux, Linda J Gaylord, Susan Bann, Carla Pierl, Christiane Barbara Lohr, Kathleen N BMJ Research Study question What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults? Methods This was a systematic review including qualitative assessment and meta-analyses using random and fixed effects models. Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature were searched from January1990 through January 2015. The 11 randomized controlled trials included compared a second generation antidepressant CBT. Ten trials compared antidepressant monotherapy with CBT alone; three compared antidepressant monotherapy with antidepressant plus CBT. Summary answer and limitations Meta-analyses found no statistically significant difference in effectiveness between second generation antidepressants and CBT for response (risk ratio 0.91, 0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change in 17 item Hamilton Rating Scale for Depression score (weighted mean difference, −0.38, −2.87 to 2.10). Similarly, no significant differences were found in rates of overall study discontinuation (risk ratio 0.90, 0.49 to 1.65) or discontinuation attributable to lack of efficacy (0.40, 0.05 to 2.91). Although more patients treated with a second generation antidepressant than receiving CBT withdrew from studies because of adverse events, the difference was not statistically significant (risk ratio 3.29, 0.42 to 25.72). No conclusions could be drawn about other outcomes because of lack of evidence. Results should be interpreted cautiously given the low strength of evidence for most outcomes. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with CBT, and many of the included trials had methodological shortcomings that may limit confidence in some of the findings. What this study adds Second generation antidepressants and CBT have evidence bases of benefits and harms in major depressive disorder. Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences. Funding, competing interests, data sharing This project was funded under contract from the Agency for Healthcare Research and Quality by the RTI-UNC Evidence-based Practice Center. Detailed methods and additional information are available in the full report, available at http://effectivehealthcare.ahrq.gov/. BMJ Publishing Group Ltd. 2015-12-08 /pmc/articles/PMC4673103/ /pubmed/26645251 http://dx.doi.org/10.1136/bmj.h6019 Text en © Amick et al 2015 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Amick, Halle R
Gartlehner, Gerald
Gaynes, Bradley N
Forneris, Catherine
Asher, Gary N
Morgan, Laura C
Coker-Schwimmer, Emmanuel
Boland, Erin
Lux, Linda J
Gaylord, Susan
Bann, Carla
Pierl, Christiane Barbara
Lohr, Kathleen N
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title_full Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title_fullStr Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title_full_unstemmed Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title_short Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
title_sort comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673103/
https://www.ncbi.nlm.nih.gov/pubmed/26645251
http://dx.doi.org/10.1136/bmj.h6019
work_keys_str_mv AT amickhaller comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT gartlehnergerald comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT gaynesbradleyn comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT forneriscatherine comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT ashergaryn comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT morganlaurac comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT cokerschwimmeremmanuel comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT bolanderin comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT luxlindaj comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT gaylordsusan comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT banncarla comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT pierlchristianebarbara comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis
AT lohrkathleenn comparativebenefitsandharmsofsecondgenerationantidepressantsandcognitivebehavioraltherapiesininitialtreatmentofmajordepressivedisordersystematicreviewandmetaanalysis